Testicular cancer is the most common malignancy among men between 14 and 44 years of age and, although it has a cure rate of >90%, some patients become refractory to chemotherapy or have a late relapse. As the Primer notes, an improved understanding of the molecular determinants underlying tumour sensitivity and resistance may lead to the development of novel therapies for these patients.
The Primer provides a comprehensive overview of the potential causes of testicular cancer, how the disease is diagnosed and staged, and the available treatment options. It also discusses challenges and research goals in an accessible format.
Nature Reviews Disease Primers (@DiseasePrimers) is a Nature Research journal that was launched in 2015 to provide broad review articles on various health fields.
Written By: Liang Cheng, MD, Departments of Pathology and Laboratory Medicine and Urology, Indiana University School of Medicine, Indianapolis, IN
Read the Abstract